BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Merck & Co., Inc. (MRK) Drug Shows Promise in Kid's Aging Disease Study


9/27/2012 7:47:05 AM

The first experimental drug for the treatment of progeria has brought hope for the families and people affected by the accelerated aging disease. Progeria patients who used a farnesyl transferase inhibitors (FTI) called lonafarnib were able to improve their cardiovascular health and increase their weight gain, problems usually associated with the condition. The drug was initially slated by manufacture Merck to treat brain cancer, but was found ineffective against that disease. "This is a fantastic first step," says Leslie Gordon, medical director for the Progeria Research Foundation, a physician at Boston Children's Hospital and Brown University and the mother of a child with progeria, told NPR.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES